<SEC-DOCUMENT>0001193125-26-239481.txt : 20260526
<SEC-HEADER>0001193125-26-239481.hdr.sgml : 20260526
<ACCEPTANCE-DATETIME>20260526163811
ACCESSION NUMBER:		0001193125-26-239481
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260526
DATE AS OF CHANGE:		20260526

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Kura Oncology, Inc.
		CENTRAL INDEX KEY:			0001422143
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				611547851
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37620
		FILM NUMBER:		261020541

	BUSINESS ADDRESS:	
		STREET 1:		4930 DIRECTORS PLACE, SUITE 500
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(858) 500-8800

	MAIL ADDRESS:	
		STREET 1:		4930 DIRECTORS PLACE, SUITE 500
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZETA ACQUISITION CORP III
		DATE OF NAME CHANGE:	20071227
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d124531ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy
Statement Pursuant to Section&nbsp;14(a) of the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No.<U>&#8195;</U>) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the Registrant&#8194;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a party other
than the Registrant&#8194;&#9744; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;<B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </B></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material under <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>KURA ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check all boxes that apply): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee paid previously with preliminary materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules
<FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KURA ONCOLOGY, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4930 Directors Place, Suite 500 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">San Diego, California 92121 </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUPPLEMENT TO THE PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON JUNE&nbsp;4, 2026 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This proxy statement supplement, dated May&nbsp;26, 2026 (this &#8220;Supplement&#8221;), supplements the definitive proxy statement on
Schedule 14A of Kura Oncology, Inc. (&#8220;Kura&#8221; or the &#8220;Company&#8221;), dated April&nbsp;10, 2026 (the &#8220;Proxy Statement&#8221;), for our Annual Meeting of Stockholders to be held on June&nbsp;4, 2026 (the &#8220;Annual
Meeting&#8221;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXCEPT AS SPECIFICALLY SUPPLEMENTED BY THE INFORMATION CONTAINED HEREIN, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THIS SUPPLEMENT DOES NOT MODIFY ANY OTHER INFORMATION SET FORTH IN THE PROXY STATEMENT. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Fellow Stockholders, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Chairperson of the Nominating
and Corporate Governance Committee of Kura&#8217;s Board of Directors (the &#8220;Board&#8221;), I am writing to you on behalf of the entire Board to request your support for the proposals set forth in the Proxy Statement, and in particular to ask
that you vote &#8220;For&#8221; the election of Mary T. Szela to serve on our Board for a three-year term expiring at our 2029&nbsp;Annual Meeting of Stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognize that certain proxy advisors and institutional investors may consider Ms.&nbsp;Szela to be &#8220;overboarded&#8221; given her concurrent service
as Chief Executive Officer and President of TriSalus Life Sciences, Inc. (&#8220;TriSalus&#8221;), a publicly held medical device company, and as a member of the boards of directors of Kura (since November&nbsp;2018), TriSalus (since
January&nbsp;2018), Absci Corporation, a publicly held generative AI drug creation company (since July&nbsp;2025), and Averin Capital Acquisition Corp., a SPAC that has not yet commenced any operations (since February&nbsp;2026). We are furnishing
this Supplement to address those concerns directly and to explain why we strongly believe Ms.&nbsp;Szela&#8217;s election is in the best interests of Kura and its stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why We Believe Ms.&nbsp;Szela Will Continue to be an Effective and Engaged Director on Kura&#8217;s Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ms.</I></B><B><I></I></B><B><I>&nbsp;Szela has personally assured the Board of her full commitment to her service as a director of Kura, including her
intention to reduce her public company board memberships before our 2027</I></B><B><I></I></B><B><I>&nbsp;Annual Meeting of Stockholders.</I></B> Ms.&nbsp;Szela has assured the Board that she is fully committed to her service to Kura and will
continue to dedicate the time necessary to fulfill her duties as a director. Notably, Ms.&nbsp;Szela has expressed to us her intention to step down from one of her other public company board seats prior to the filing of Kura&#8217;s proxy statement
for our 2027&nbsp;Annual Meeting of Stockholders &#8211; this commitment reflects Ms.&nbsp;Szela&#8217;s belief in Kura&#8217;s future and her prioritization of her service to our Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When recommending individuals as nominees for our Board and evaluating each director&#8217;s performance on the Board, the Board and its Nominating and
Corporate Governance Committee considers, on an annual basis, each director&#8217;s outside commitments, including directorships or leadership positions at other publicly traded and private companies and
<FONT STYLE="white-space:nowrap">non-profit&nbsp;entities,</FONT> to help determine whether a director&#8217;s outside commitments impair or could impair that director&#8217;s effectiveness as a member of our Board. Our Nominating and Corporate
Governance Committee engaged directly with Ms.&nbsp;Szela regarding her time commitments prior to recommending her for re-election, and the Board believes her personal assurance, taken together with her track record of engagement described below,
deserves meaningful weight alongside any formulaic overboarding policy threshold. Our Board intends to continue to evaluate the outside commitments and effectiveness of Ms.&nbsp;Szela, as well as each of the Board&#8217;s other directors, on a
going-forward basis. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ms.</I></B><B><I></I></B><B><I>&nbsp;Szela&#8217;s extensive experience across multiple public
biotechnology companies makes her uniquely qualified to serve on Kura&#8217;s Board. </I></B>Ms.&nbsp;Szela brings a rare combination of executive leadership and boardroom experience that is directly relevant to Kura&#8217;s stage of development and
strategic priorities.<B><I> </I></B>Her senior management and board-level experience across multiple public biotechnology companies gives her a comprehensive perspective on the challenges and opportunities Kura faces. Her expertise in pharmaceutical
operations, development and commercial strategy, strategic partnering and commercial operations makes her one of the most operationally fluent directors available to Kura, providing the Board with insights that would be difficult to replicate with
another candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ms.</I></B><B><I></I></B><B><I>&nbsp;Szela&#8217;s attendance record and quality of engagement demonstrate her commitment to,
and capacity for, service on Kura&#8217;s Board. </I></B>In 2025, Ms.&nbsp;Szela attended over 85% of our Board, Audit Committee, and Compensation Committee meetings, and since she joined our Board in November&nbsp;2018, her attendance rate has been
over 90%. She also achieved 100% attendance in 2025 across all board and committee meetings at each of the other three public company boards on which she serves, speaking directly to her ability to manage her time and prioritize her board
responsibilities. Beyond attendance, Ms.&nbsp;Szela consistently arrives prepared and contributes meaningfully to Board discussions through insightful questions and substantive comments that reflect a thorough review of Board materials, <FONT
STYLE="white-space:nowrap">pre-reads,</FONT> and Kura&#8217;s periodic filings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The substantially similar size and industry profile of the
companies on which Ms.</I></B><B><I></I></B><B><I>&nbsp;Szela serves meaningfully reduce the practical burden of her board service.</I></B> All four public companies on which Ms.&nbsp;Szela serves as a director are
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filers, making them generally comparable in size, governance complexity, and regulatory burden. Three of the four companies, including Kura, are life sciences companies, meaning
Ms.&nbsp;Szela&#8217;s expertise compounds across her board service, making her a more effective director at each company. The fourth company is a SPAC conducting an acquisition search focused on a company at the intersection of technology and
health, which directly aligns with Ms.&nbsp;Szela&#8217;s background. The convergence of company size and industry sector across Ms.&nbsp;Szela&#8217;s public company board portfolio meaningfully reduces the practical burden associated with her
service on those boards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For the foregoing reasons, our Board unanimously recommends that you vote &#8220;For&#8221; the election of Ms.&nbsp;Szela at
the Annual Meeting. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you for your consideration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g124531g35h76.jpg" ALT="LOGO" STYLE="width:1.72292in;height:0.445139in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Thomas Malley </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairperson of Kura&#8217;s Nominating and Corporate Governance Committee </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">**** </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VOTING MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as described in this Supplement, the information provided in the Proxy Statement continues to apply and should be considered in voting your shares of
Kura common stock. There are no changes to the proxy card or voting instruction form previously mailed to stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you have already
submitted your vote, then you do not need to take any action unless you wish to change your vote. If you have not yet voted, please do so as soon as possible. If you have already voted and wish to change your vote based on any of the information
contained in this Supplement or otherwise, you may revoke your proxy and change your vote at any time before the final vote at the Annual Meeting.</I></B> Important information regarding </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
how to vote your shares of Kura common stock and how to revoke a proxy already given is available in the Proxy Statement under the captions &#8220;Questions and Answers About these Proxy
Materials and Voting &#8211; How do I vote?&#8221; and &#8220;Questions and Answers About these Proxy Materials and Voting &#8211; Can I change my vote after submitting my proxy?&#8221;, respectively. Votes already cast will remain valid and will be
voted at the Annual Meeting unless changed or revoked. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g124531g35h76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g124531g35h76.jpg
M_]C_X0O[17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    ?    <@$R  (    4
M    D8=I  0    !    J    -0 "OR    G$  *_(   "<0061O8F4@4&AO
M=&]S:&]P(#(R+C @*%=I;F1O=W,I #(P,C8Z,#4Z,C<@,#$Z,3 Z,#0
M  .@ 0 #     ?__  "@ @ $     0   *.@ P $     0   "H
M!@$#  ,    !  8   $:  4    !   !(@$;  4    !   !*@$H  ,    !
M  (   (!  0    !   !,@("  0    !   *P0        !(     0   $@
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M)U?_  2Z1))3_]G_[1/>4&AO=&]S:&]P(#,N,  X0DE-!"4      !
M                .$))300Z      #E    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0%(            *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M       $    'CA"24T#\P      "0           0 X0DE-)Q        H
M 0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ !
M *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M   !.$))30/X      !P  #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  -C    !@              *@   *,    7 %0 : !O &T 80!S "  30!A
M &P ; !E 'D ( !3 &D 9P!N &$ = !U '( 90    $
M         0              HP   "H                      0
M                   0     0       &YU;&P    "    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   "H     4F=H=&QO;F<   "C    !G-L
M:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)
M1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M#$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M"D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<    J     %)G:'1L;VYG    HP    -U<FQ415A4     0
M &YU;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%
M6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%
M6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
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MPX[07$ $G\WW)*9I+(^M/UDQ/JUTBSJ62TVF17CT-T-EK@?3JW?F?1<^Q_\
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M(" @(" @(#P_>'!A8VME="!E;F0](G<B/S[_[@ .061O8F4 9$     !_]L
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M>>P.3@)L3#78NOBE7_!O>^M]+7W[KW7O?NO=$G^?'S$I/A)TEMKM!=J4N_\
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ME3!!39#']Y?-=%@D5D5&QY#E#ZC[Y]>K3(_U?ZOSZV&^D/E+6?&/_A.]\?\
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MM?9V#[0W)L:NWSYL\FQ\SNS);#@RU742)AA$ZPI[KW14?AO_ ".<UU]\=/\
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EX]3_ )F;A_\ F2W_ (%7_P ^W_[.?[?WH^76CY=&Y][ZWU__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
